Management of gastrointestinal complications in patients undertaking low-dose aspirin after percutaneous coronary interventions (PCI)
Not Applicable
Recruiting
- Conditions
- In patient underwent PCI, low-dose aspirin undertaking for 6 months or more for the prevention of restenosis
- Registration Number
- JPRN-UMIN000002460
- Lead Sponsor
- Stearing committee for LA-Study
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 360
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Hypersinsitivity for any drugs (2)Patient undertaking atazanavir sulfate (3)Patient with severe hepatic and/or renal disorders required any therapy (4)Patient with severe heart and/or lung disorders required any therapy (5)Pregnancy, possible pregnancy, or pregnancy hopeful (6)Upper gastrointestinal disorders (ulcer with hemrrhage, erosion unknown upper gastrointestinal hemmorhage (7)PPI taken with past 3 months (8)Patient with malignant neoplasm (9)Patient with surgery at esophagas duodenal and/or stomach (10)Perticipant in any other clinical trials within past 1 month (11)Patient whom investigators/physicins assessed inappropriate as a participant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method